Advertisement

Medical Management of Ulcerative Colitis: Conventional Therapy—Azathioprine

  • Barrett G. Levesque
  • Edward V. LoftusJr.Email author
Chapter

Abstract

Azathioprine and 6-mercaptopurine are effective therapies for maintaining steroid-free remission for many patients with ulcerative colitis. Genetic variation in the population leading to variable thiopurine metabolism warrants initial and ongoing laboratory monitoring throughout the course of treatment for dose-dependent toxicities such as leukopenia and hepatic biochemical abnormalities. Dose-independent toxicity, such as fever, pancreatitis, or flu-like illness, often occurs in the first few weeks of therapy, but some reactions (e.g., nausea) may be avoided by switching from azathioprine to 6-mercaptopurine. Infections are a primary risk of long-term therapy. There is an elevated relative risk of lymphoma during therapy; however, the absolute risk is relatively low. Future clinical trials may determine if the combination of azathioprine and biologic therapy is more effective in ulcerative colitis than either therapy alone.

Keywords

Azathioprine Ulcerative colitis 

References

  1. 1.
    Dearing WH, Brown PW. Experiences with cortisone and ACTH in chronic ulcerative colitis. Proc Staff Meet Mayo Clin. 1950;25:486–8.PubMedGoogle Scholar
  2. 2.
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Lennard-Jones JE, Misiewicz JJ, Connell AM, Baron JH, Jones FA. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet. 1965;1:188–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Bowen GE, Irons Jr GV, Rhodes JB, Kirsner JB. Early experiences with azathioprine in ulcerative colitis; a note of caution. JAMA. 1966;195:460–4.CrossRefPubMedGoogle Scholar
  5. 5.
    Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J. 1974;4:627–30.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Caprilli R, Carratu R, Babbini M. Double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. Preliminary report Am J Dig Dis. 1975;20:115–20.CrossRefPubMedGoogle Scholar
  7. 7.
    Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed). 1982;284:1291–2.CrossRefGoogle Scholar
  8. 8.
    Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology. 1975;69:96–9.PubMedGoogle Scholar
  9. 9.
    Elion G. The comparative metabolism of Imuran and 6-mercaptopurine in man. Proc Am Assoc Cancer Res. 1969;10:21.Google Scholar
  10. 10.
    De Miranda P, Beacham 3rd LM, Creagh TH, Elion GB. The metabolic fate of the methylnitroimidazole moiety of azathioprine in the rat. J Pharmacol Exp Ther. 1973;187:588–601.PubMedGoogle Scholar
  11. 11.
    Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91:423–33.PubMedGoogle Scholar
  12. 12.
    Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329–39.CrossRefPubMedGoogle Scholar
  13. 13.
    Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651–62.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Lennard L, Harrington CI, Wood M, Maddocks JL. Metabolism of azathioprine to 6-thioguanine nucleotides in patients with pemphigus vulgaris. Br J Clin Pharmacol. 1987;23:229–33.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Sandborn WJ, Van OEC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn’s disease. Gastroenterology. 1995;109:1808–17.CrossRefPubMedGoogle Scholar
  16. 16.
    Mahadevan U, Tremaine WJ, Johnson T, Pike MG, Mays DC, Lipsky JJ, et al. Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol. 2000;95:3463–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn’s disease. North American Azathioprine Study Group. Gastroenterology. 1999;117:527–35.CrossRefPubMedGoogle Scholar
  18. 18.
    Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132–42.CrossRefPubMedGoogle Scholar
  19. 19.
    Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705–13.CrossRefPubMedGoogle Scholar
  20. 20.
    Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut. 2001;48:642–6.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006;130:1047–53.CrossRefPubMedGoogle Scholar
  22. 22.
    Reinshagen M, Schutz E, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, et al. 6-Thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. Clin Chem. 2007;53:1306–14.CrossRefPubMedGoogle Scholar
  23. 23.
    Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007;5:209–14.CrossRefPubMedGoogle Scholar
  24. 24.
    Gardiner SJ, Gearry RB, Burt MJ, Chalmers-Watson T, Chapman BA, Ross AG, et al. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. J Gastroenterol Hepatol. 2011;26:49–54.CrossRefPubMedGoogle Scholar
  25. 25.
    Ansari A, Elliott T, Baburajan B, Mayhead P, O’Donoghue J, Chocair P, et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:734–41.Google Scholar
  26. 26.
    Ansari A, Patel N, Sanderson J, O’Donoghue J, Duley JA, Florin TH. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:640–7.Google Scholar
  27. 27.
    Govani SM, Higgins PD. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. J Crohns Colitis. 2010;4:444–9.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Leung Y, Sparrow MP, Schwartz M, Hanauer SB. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohns Colitis. 2009;3:162–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Geller SA, Dubinsky MC, Poordad FF, Vasiliauskas EA, Cohen AH, Abreu MT, et al. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol. 2004;28:1204–11.CrossRefPubMedGoogle Scholar
  30. 30.
    Leung Y, Panaccione R, Hemmelgarn B, Jones J. Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. Dig Dis Sci. 2008;53:1455–61.CrossRefPubMedGoogle Scholar
  31. 31.
    Gisbert JP, Linares PM, McNicholl AG, Mate J, Gomollon F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009;30:126–37.CrossRefPubMedGoogle Scholar
  32. 32.
    Levesque BG, Olkin I. Azathioprine and ulcerative colitis: a “second-look” meta-analysis. Dig Dis Sci. 2010;55:1186–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Sood A, Midha V, Sood N, Kaushal V. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol. 2000;19:14–6.PubMedGoogle Scholar
  34. 34.
    Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47–53.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992;305:20–2.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Sood A, Kaushal V, Midha V, Bhatia KL, Sood N, Malhotra V. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol. 2002;37:270–4.CrossRefPubMedGoogle Scholar
  37. 37.
    Sood A, Midha V, Sood N, Avasthi G. Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol. 2003;22:79–81.PubMedGoogle Scholar
  38. 38.
    Cassinotti A, Actis GC, Duca P, Massari A, Colombo E, Gai E, et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol. 2009;104:2760–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;9:CD000478.Google Scholar
  40. 40.
    Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993;34:1081–5.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Lewis JD, Abramson O, Pascua M, Liu L, Asakura LM, Velayos FS, et al. Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations. Clin Gastroenterol Hepatol. 2009;7:1195–201. quiz 1141–2.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118:1025–30.CrossRefPubMedGoogle Scholar
  43. 43.
    Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, Banks P, et al. 5-Aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis. 2006;12:251–7.CrossRefPubMedGoogle Scholar
  44. 44.
    Thomas Jr CW, Lowry PW, Franklin CL, Weaver AL, Myhre GM, Mays DC, et al. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis. 2003;9:237–45.CrossRefPubMedGoogle Scholar
  45. 45.
    Lees CW, Maan AK, Hansoti B, Satsangi J, Arnott ID. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:220–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Weersma RK, Peters FT, Oostenbrug LE, van den Berg AP, van Haastert M, Ploeg RJ, et al. Increased incidence of azathioprine-induced pancreatitis in Crohn’s disease compared with other diseases. Aliment Pharmacol Ther. 2004;20:843–50.CrossRefPubMedGoogle Scholar
  47. 47.
    Bermejo F, Lopez-Sanroman A, Taxonera C, Gisbert JP, Perez-Calle JL, Vera I, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther. 2008;28:623–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Toruner M, Loftus Jr EV, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–36.CrossRefPubMedGoogle Scholar
  49. 49.
    Aberra FN, Stettler N, Brensinger C, Lichtenstein GR, Lewis JD. Risk for active tuberculosis in inflammatory bowel disease patients. Clin Gastroenterol Hepatol. 2007;5:1070–5.CrossRefPubMedGoogle Scholar
  50. 50.
    Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621–30.CrossRefPubMedGoogle Scholar
  51. 51.
    Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101:1834–40.CrossRefPubMedGoogle Scholar
  52. 52.
    Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010;105:1231–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121–5.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874–81.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, Cosnes J, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.CrossRefPubMedGoogle Scholar
  56. 56.
    Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847–58.e4. quiz e48–50.CrossRefPubMedGoogle Scholar
  57. 57.
    Khan N, Abbas AM, Lichtenstein GR, Loftus Jr EV, Bazzano LA. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013;145:1007–15.e3.CrossRefPubMedGoogle Scholar
  58. 58.
    Dayharsh GA, Loftus Jr EV, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002;122:72–7.CrossRefPubMedGoogle Scholar
  59. 59.
    Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265–7.CrossRefPubMedGoogle Scholar
  60. 60.
    Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:36–41.e1.CrossRefPubMedGoogle Scholar
  61. 61.
    Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268–74.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Long MD, Kappelman MD, Pipkin CA. Nonmelanoma skin cancer in inflammatory bowel disease: a review. Inflamm Bowel Dis. 2011;17(6):1423–7.CrossRefPubMedGoogle Scholar
  63. 63.
    Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol. 1984;6:211–6.PubMedGoogle Scholar
  64. 64.
    Bush MC, Patel S, Lapinski RH, Stone JL. Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med. 2004;15:237–41.CrossRefPubMedGoogle Scholar
  65. 65.
    Coelho J, Beaugerie L, Colombel JF, Hebuterne X, Lerebours E, Lemann M, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut. 2011;60:198–203.CrossRefPubMedGoogle Scholar
  66. 66.
    Dominitz JA, Young JC, Boyko EJ. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. Am J Gastroenterol. 2002;97:641–8.CrossRefPubMedGoogle Scholar
  67. 67.
    Nguyen GC, Boudreau H, Harris ML, Maxwell CV. Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol. 2009;7:329–34.CrossRefPubMedGoogle Scholar
  68. 68.
    Mahadevan U, Martin CF, Sandler RS, Kane SV, Dubinsky M, Lewis JD, et al. A multi-center national prospective study of pregnancy and neonatal outcomes in women with inflammatory bowel disease exposed to immunomodulators and biologic therapy. Gastroenterology. 2009;136:A-88.Google Scholar
  69. 69.
    Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Division of GastroenterologyUniversity of California San DiegoLa JollaUSA
  2. 2.Division of Gastroenterology & HepatologyMayo ClinicRochesterUSA

Personalised recommendations